

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

# MIV Global Medtech Fund

(the "Sub-Fund")

|   |              |  |
|---|--------------|--|
| ISIN  | LU1050446076 | Product Manufacturer: Vontobel Asset Management S.A.         |
| Share Class (the "Shares")                    | N3           | 18, rue Erasme L-1468 Luxembourg                             |
| Currency                                      | USD          | Telephone number: +352 26 34 74 1                            |
| a sub-fund of Variopartner SICAV (the "Fund") |              | <a href="http://www.vontobel.com/AM">www.vontobel.com/AM</a> |

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising Vontobel Asset Management S.A. in relation to this Key Information Document. This Product and its management company Vontobel Asset Management S.A. are authorized in Luxembourg and supervised / regulated by the CSSF. Vontobel Asset Management S.A. is part of Vontobel Group.

This Key Information Document is accurate as at 22 March 2024.

## What is this product?

### Type

The Fund was incorporated as a société anonyme, an open-ended fund formed under the amended law of 17 December 2010 on undertakings for collective investment. It is an umbrella fund with multiple compartments, the Sub-Fund being one of these compartments. The Shares are a class of shares in the Sub-Fund.

### Objective

This actively managed sub-fund aims to achieve the highest possible capital growth. It is categorized as Article 8 SFDR. More details on the above can be found in the prospectus.

The sub-fund invests at least two-thirds of its assets in equities and equity-like instruments. It may also hold cash up to 20% of its net assets.

**Type of approach:** The sub-fund invests in securities of listed companies primarily operating in medical technology (research, development, manufacturing and distribution). The sub-fund performs its analysis and investments around the world. The Sub-Fund promotes environmental and social characteristics by following integration and exclusion approaches by investing in medical technology companies with good Environmental, Social and Governance (ESG) profiles according to the analysis of the Investment Manager. Companies must have a minimum ESG profile based on the Investment Manager's ESG framework. The implementation of the sustainability selection criteria leads to the exclusion of at least 20% of the initial investment universe, which consists of all medical technology companies worldwide. **Threshold:** At least 95% of the securities in the Sub-Fund have the sustainability selection criteria applied. The Sub-Fund invests in direct holdings in order to meet the promoted environmental or social characteristics. **Main methodological limits:** potential inconsistency, inaccuracy or lack of availability of ESG data issued by external third party providers.

The sub-fund may use derivatives for hedging purposes.

The currency of this class is NOT hedged against the sub-fund's main currency. The investor consequently bears the full currency risk.

**Redemption of shares:** daily when banks in Luxembourg are open for normal business (see prospectus for details and exceptions).

Any income generated will be reinvested and included in the value of your Shares.

The Sub-Fund is not managed with reference to a benchmark. The portfolio manager has full investment discretion within the predefined investment limits.

N3 shares may be subscribed only by investors in the United Kingdom and the Netherlands and by investors acting on their own behalf or on behalf of their own clients and who have concluded a separate agreement with their clients. The shares do not grant any rebates or retrocessions to the investors.

Taking into consideration the minimum recommended holding period, the return will depend on the performance of the underlying investments.

The Fund's depositary is CACEIS Investor Services Bank S.A.

This sub-fund is part of an umbrella fund. The various sub-funds are not liable for one another, i.e. only the gains and losses of this sub-fund are relevant for you as an investor. You can request the conversion of some or all of your shares in the sub-fund in accordance with the rules set out in the sales prospectus.

You can find the sales prospectus, up-to-date semi-annual and annual reports, share prices as well as other practical information on the fund in English and German free of charge at: [www.mivglobalmedtech.ch](http://www.mivglobalmedtech.ch).

### Intended Retail Investor

The sub-fund is intended for retail investors with knowledge and/or experience of these types of products, that have obtained appropriate investment advice, that have medium to long-term investment horizon and that have the ability to bear losses up to the amount they have invested in the sub-fund.

### Term

The Shares do not have a maturity date. The Product Manufacturer can terminate the Shares unilaterally. The Shares, the Sub-Fund and the Fund can be terminated early and liquidated in the cases set out in the prospectus and the articles of incorporation of the Fund.

## What are the risks and what could I get in return?

The summary risk indicator (the “SRI”) is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact our capacity to pay you.

**Be aware of currency risk. In some circumstances, you may receive payments in a different currency, so the final return you will get may depend on the exchange rate between the two currencies. This risk is not considered in the SRI.**

Other risks not captured in the SRI: liquidity, operational, legal or sustainability risks. Further details in the prospectus.

This product does not include any protection from future market performance so you could lose some or all of your investment.

The Product offers no capital guarantee against credit risk.

◀ Lower risk

Higher risk ▶



The risk indicator assumes you keep the product for 5 years. We have classified this product as 5 out of 7, which is a medium-high risk class.

## Performance Scenarios

The figures shown include all the costs of the product itself but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavorable, moderate, and favorable scenarios shown are illustrations using the worst, average, and best performance of the product, a suitable benchmark and/or a proxy over the last 10 years.

| Recommended holding period: |   | 5 years                  |                           |
|-----------------------------|---|--------------------------|---------------------------|
| Example Investment:         |   | USD 10,000               |                           |
|                             |   | If you exit after 1 year | If you exit after 5 years |
| <b>Scenarios</b>            |   |                          |                           |
| <b>Minimum</b>              | There is no minimum guaranteed return. You could lose some or all of your investment. |                          |                           |
| <b>Stress</b>               | <b>What you might get back after costs</b>  | USD 5,200                | USD 2,640                 |
|                             | <b>Average return each year</b>   | -47.96%                  | -23.41%                   |
| <b>Unfavourable</b>         | <b>What you might get back after costs</b>  | USD 8,870                | USD 6,740                 |
|                             | <b>Average return each year</b>   | -11.32%                  | -7.60%                    |
| <b>Moderate</b>             | <b>What you might get back after costs</b>  | USD 10,810               | USD 18,160                |
|                             | <b>Average return each year</b>   | 8.15%                    | 12.68%                    |
| <b>Favourable</b>           | <b>What you might get back after costs</b>  | USD 11,440               | USD 24,050                |
|                             | <b>Average return each year</b>   | 14.39%                   | 19.18%                    |

The stress scenario shows what you might get back in extreme market circumstances.

This type of scenario occurred for an investment between: (Favourable: February 2016 - February 2021, Moderate: August 2015 - August 2020, Unfavourable: September 2021 - March 2024).

## What happens if Vontobel Asset Management S.A. is unable to pay out?

The investor may not face a financial loss due to the default of the Product Manufacturer.

The assets of the Fund are held in safekeeping by its depositary, CACEIS Investor Services Bank S.A. (the “Depositary”). In the event of the insolvency of the Product Manufacturer, the Fund’s assets in the safekeeping of the Depositary will not be affected. However, in the event of the Depositary’s insolvency, or someone acting on its behalf, the Fund may suffer a financial loss. This risk is mitigated to a certain extent by the fact that the Depositary is required by law and regulation to segregate its own assets from the assets of the Fund. The Depositary will also be liable to the Fund for any loss arising from, among other things, its negligence, fraud or intentional failure properly to fulfill its obligations (subject to certain limitations as set out in the agreement with the Depositary).

Losses are not covered by an investor compensation or guaranteed scheme.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Cost over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- USD 10,000 is invested.

|                               | If you exit after 1 year | If you exit after 5 years |
|-------------------------------|--------------------------|---------------------------|
| <b>Total costs</b>            | USD 612                  | USD 1,240                 |
| <b>Annual cost impact (*)</b> | 6.9%                     | 2.3% each year            |

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 15.02% before costs and 12.68% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

These figures include the maximum distribution fee that the person selling you the product may charge.

## Composition of costs

| One-off costs upon entry or exit                                   |   | If you exit after 1 year |
|--|---|--------------------------|
| <b>Entry costs</b>   | 5.00% of the amount you pay in when entering this investment. This is the maximum that might be taken out of your money before it is invested.  | Up to USD 500            |
| <b>Exit costs</b>  | There is no exit fee charged on this product.   | USD 0                    |
| Ongoing costs taken each year                                      |   |                          |
| <b>Management fees and other administrative or operating costs</b> | 1.17% of the value of your investment per year. This is an estimate based on actual costs over the last year.   | USD 111                  |
| <b>Transaction costs</b>   | 0.01% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell. | USD 1                    |
| Incidental costs taken under specific conditions                   |   |                          |
| <b>Performance fees</b>  | There is no performance fee for this product.   | USD 0                    |

Conversion costs: instead of exit + entry costs, you may be charged 1.50% in case you switch your investment to another Product in the Fund.

### How long should I hold it and can I take money out early?

Recommended holding period: 5 years

Based on the investment policy and the risk profile of the Sub-Fund, a holding period of 5 years is recommended. Investors can sell the investment at any time, irrespective of the recommended holding period, without additional cost. Shares can be sold daily (on business days). Exit costs are presented above.

### How can I complain?

If you have a complaint about the product or the person advising on or selling the product you will need to provide the details to the person who advised you or sold you the product. Complaints about the management company or the Key Information Document should be sent to Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg or [luxembourg@vontobel.com](mailto:luxembourg@vontobel.com). You can also visit [www.vontobel.com/vamsa](http://www.vontobel.com/vamsa) for more information.

### Other relevant information

The information contained in this Key Information Document is supplemented by the articles of incorporation and the prospectus, which will be provided to retail investors before subscription. Further information about the Fund, including a copy of the prospectus, latest annual report and any subsequent half-yearly report can be found in English and/or German at [www.mivglobalmedtech.ch](http://www.mivglobalmedtech.ch) free of charge. The Key Information Document is available on the Product Manufacturer's website at [www.vontobel.com/AM](http://www.vontobel.com/AM). A paper copy of the Key Information Document is available upon request, free of charge, from the Product Manufacturer.

Information about past performance can be found at [https://docs.publifund.com/pastperf/LU1050446076/en\\_DE](https://docs.publifund.com/pastperf/LU1050446076/en_DE). Past performance data is presented for 9 years.

The previous performance scenario calculations are available at [https://docs.publifund.com/monthlyperf/LU1050446076/en\\_DE](https://docs.publifund.com/monthlyperf/LU1050446076/en_DE).